Back to Search
LEAH SCHAAF, DO
DO
Pediatrics Physician
NPI: 1205417342Individual
Specialties, Licenses & Credentials
Student in an Organized Health Care Education/Training Program
Student in an Organized Health Care Education/Training Program
Code: 390200000X
Pediatrics PhysicianPrimary
Pediatrics
Code: 208000000X
76374(MN)
Research & Publications (20)
Phase I and pharmacokinetic study of mitomycin C and celecoxib as potential modulators of tumor resistance to irinotecan in patients with solid malignancies.
PMID 18795290·Cancer Chemother Pharmacol·2009
3-trial
Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia.
PMID 18981292·Blood·2009
3-trial
Enterohepatic recirculation model of irinotecan (CPT-11) and metabolite pharmacokinetics in patients with glioma.
PMID 18496691·Cancer Chemother Pharmacol·2009
8-other
Development and validation of a highly sensitive liquid chromatography/mass spectrometry method for simultaneous quantification of lenalidomide and flavopiridol in human plasma.
PMID 18708993·Ther Drug Monit·2008
3-trial
Age-related penetrance of endocrine tumours in multiple endocrine neoplasia type 1 (MEN1): a multicentre study of 258 gene carriers.
PMID 17590169·Clin Endocrinol (Oxf)·2007
4-observational
Developing effective screening strategies in multiple endocrine neoplasia type 1 (MEN 1) on the basis of clinical and sequencing data of German patients with MEN 1.
PMID 17853334·Exp Clin Endocrinol Diabetes·2007
8-other
Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia.
PMID 17003373·Blood·2007
3-trial
Thalidomide and celecoxib as potential modulators of irinotecan's activity in cancer patients.
PMID 16685529·Cancer Chemother Pharmacol·2007
8-other
Clinical pharmacodynamic effects of the growth hormone receptor antagonist pegvisomant: implications for cancer therapy.
PMID 17289896·Clin Cancer Res·2007
3-trial
Phase I/pilot study of SU5416 (semaxinib) in combination with irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer.
PMID 16601426·Am J Clin Oncol·2006
3-trial
A phase I and pharmacokinetic study of a powder-filled capsule formulation of oral irinotecan (CPT-11) given daily for 5 days every 3 weeks in patients with advanced solid tumors.
PMID 16328416·Cancer Chemother Pharmacol·2006
3-trial
Assessment of tumor necrosis factor alpha blockade as an intervention to improve tolerability of dose-intensive chemotherapy in cancer patients.
PMID 16622259·J Clin Oncol·2006
2-rct
Changes in weight and glucose tolerance during treatment with mirtazapine.
PMID 16373922·Diabetes Care·2006
8-other
Discrepant results in the diagnosis of GH deficiency with the insulin-tolerance test and the GHRH plus arginine test in patients with traumatic brain injury.
PMID 16990654·Eur J Endocrinol·2006
4-observational
Phase 1 and pharmacokinetic study of intravenous irinotecan in refractory solid tumor patients with hepatic dysfunction.
PMID 16778106·Clin Cancer Res·2006
3-trial
[62 year-old patient with rapid progressive edema, low potassium and hypertension].
PMID 16470359·Internist (Berl)·2006
5-case
The influence of 4-week treatment with sertraline on the combined T3/TRH test in depressed patients.
PMID 15747035·Eur Arch Psychiatry Clin Neurosci·2005
3-trial
Gamma-knife surgery is effective in normalising plasma insulin-like growth factor I in patients with acromegaly.
PMID 15891958·Exp Clin Endocrinol Diabetes·2005
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 2450 RIVERSIDE AVE # M136
MINNEAPOLIS, MN 55454 - Phone
- (612) 624-4477
Quick Facts
- NPI
- 1205417342
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 2
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile